Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
11:00am, Friday, 20'th May 2022 GlobeNewswire Inc.
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tra
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
07:00am, Friday, 20'th May 2022
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop trans
Why Shares of BioXcel Therapeutics Climbed 25.2% This Week
08:36pm, Thursday, 19'th May 2022 The Motley Fool
With the company's launch of its first marketed drug on the horizon, investors showed some excitement.
Why Shares of BioXcel Therapeutics Climbed 25.2% This Week
04:36pm, Thursday, 19'th May 2022
With the company's launch of its first marketed drug on the horizon, investors showed some excitement.
BioXcel Therapeutics (BTAI) CEO, Vimal Mehta on Q1 2022 Results - Earnings Call Transcript
11:21am, Monday, 09'th May 2022
BioXcel Therapeutics Inc. (NASDAQ:BTAI ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer Matt Wiley - Chief Commercial Officer Richar
Why BioXcel Therapeutics Shares Went Up 12.9% This Week
08:54pm, Thursday, 05'th May 2022 The Motley Fool
The company is stepping up its efforts to expand the label uses of its lead therapy.
Why BioXcel Therapeutics Shares Went Up 12.9% This Week
04:54pm, Thursday, 05'th May 2022
The company is stepping up its efforts to expand the label uses of its lead therapy.
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
2 Small-Cap Stocks With Monster Upsides, According to Wall Street
03:15pm, Saturday, 30'th Apr 2022 The Motley Fool
Sometimes analysts are on the spot, and other times, not so much.
2 Small-Cap Stocks With Monster Upsides, According to Wall Street
11:15am, Saturday, 30'th Apr 2022
Sometimes analysts are on the spot, and other times, not so much.
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
07:00am, Tuesday, 26'th Apr 2022
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identi
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
11:05am, Tuesday, 19'th Apr 2022 GlobeNewswire Inc.
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need
BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority
11:00am, Tuesday, 19'th Apr 2022 GlobeNewswire Inc.
Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development
BioXcel Therapeutics: At A Turning Point After The Approval Of BXCL501
04:59pm, Friday, 08'th Apr 2022
On April 6, BioXcel announced the FDA's approval of BXCL501 to treat acute agitation in patients with schizophrenia and bipolar syndrome.
Best Stocks To Buy Now? 3 Health Care Stocks For Your List
02:30pm, Friday, 08'th Apr 2022
Could health care stocks be the play amidst the current volatility in markets?
